Table 3.
Recombinant factor VIII therapies
| Product Name | Company | Product generation | Blood-based additives in processing | Available dosage strengths (International Units) | Diluent volume (ml) | Year product introduced |
|---|---|---|---|---|---|---|
| Recombinate® | Baxter Healthcare | First (Full-length molecule) | Yes | 250, 500, 1000 | 10 | 1992 |
| Kogenate® FSa | Bayer Healthcare | Second (Full-length molecule) | Yes | 250, 500, 1000, 2000 | 2.5 for 250, 500 and 1000 IU, 5 for 2000 IU | 2000 |
| ReFacto® | Wyeth Pharmaceuticals | Second (B domain-deleted molecule) | Yes | 250, 500, 1000, 2000 | 4 | 2000 |
| Advate® | Baxter Healthcare | Third (Full length molecule) | No | 250, 500, 1000, 1500, 2000, 3000 | 5 | 2003 |
| Xyntha™ | Wyeth Pharmaceuticals | Third (B domain-deleted molecule) | No | 250, 500, 1000, 2000 | 4 | 2008 |
a
Kogenate® FS is also marketed as Helixate® FS by CSL Behring.